GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (STU:ECX) » Definitions » Cyclically Adjusted PB Ratio

Epigenomics AG (STU:ECX) Cyclically Adjusted PB Ratio : 0.01 (As of Sep. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG Cyclically Adjusted PB Ratio?

As of today (2024-09-22), Epigenomics AG's current share price is €0.646. Epigenomics AG's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was €51.31. Epigenomics AG's Cyclically Adjusted PB Ratio for today is 0.01.

The historical rank and industry rank for Epigenomics AG's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:ECX's Cyclically Adjusted PB Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.05
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Epigenomics AG's adjusted book value per share data for the three months ended in Jun. 2023 was €2.237. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €51.31 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Epigenomics AG Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Epigenomics AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Cyclically Adjusted PB Ratio Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.97 2.57 0.86 0.22 0.16

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.12 0.16 0.06 0.08

Competitive Comparison of Epigenomics AG's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Epigenomics AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Cyclically Adjusted PB Ratio falls into.



Epigenomics AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Epigenomics AG's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.646/51.31
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epigenomics AG's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Epigenomics AG's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=2.237/123.1404*123.1404
=2.237

Current CPI (Jun. 2023) = 123.1404.

Epigenomics AG Quarterly Data

Book Value per Share CPI Adj_Book
201309 43.410 98.983 54.005
201312 67.726 99.356 83.939
201403 68.515 99.543 84.757
201406 50.015 99.543 61.872
201409 30.698 99.823 37.869
201412 54.125 99.543 66.956
201503 37.740 99.717 46.605
201506 71.372 100.417 87.523
201509 59.592 100.417 73.077
201512 56.549 99.717 69.833
201603 41.197 100.017 50.722
201606 64.836 100.717 79.271
201609 48.043 101.017 58.565
201612 91.418 101.217 111.219
201703 77.746 101.417 94.399
201706 53.679 102.117 64.730
201709 82.430 102.717 98.820
201712 63.472 102.617 76.166
201803 46.117 102.917 55.179
201806 30.245 104.017 35.805
201809 10.066 104.718 11.837
201812 78.822 104.217 93.134
201903 66.846 104.217 78.983
201906 49.560 105.718 57.728
201909 37.795 106.018 43.899
201912 34.867 105.818 40.575
202003 20.975 105.718 24.432
202006 24.470 106.618 28.262
202009 18.541 105.818 21.576
202012 12.922 105.518 15.080
202103 10.960 107.518 12.553
202106 10.760 108.486 12.213
202109 31.190 109.435 35.096
202112 28.469 110.384 31.759
202203 23.338 113.968 25.216
202206 20.378 115.760 21.677
202209 17.036 118.818 17.656
202212 12.427 119.345 12.822
202303 5.550 122.402 5.583
202306 2.237 123.140 2.237

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Epigenomics AG  (STU:ECX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Epigenomics AG Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.